Expert Analysis

Investigational Antiretrovirals

Source: CCO Official Conference Coverage of the 4th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention

Investigational Antiretrovirals

Faculty:

Pedro Cahn, MD, PhD
Joseph J. Eron, Jr., MD
Daniel R. Kuritzkes, MD

CME CREDIT INFORMATION

Release Date: 09/14/07

Expiration Date: 09/13/08

Physicians: maximum of 1.25 AMA PRA Category 1 Credits™

Registered Nurses: 1.2 Nursing CE credits

Pharmacists: 1.2 contact hours (0.12 CEUs)

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Identify investigational antiretrovirals in early or late stages of clinical development
Summarize the results of recent clinical studies involving investigational antiretrovirals
Specify which investigational agents have been studied in treatment-naive vs treatment-experienced patients

Topics covered include:

DUET-1 and -2: Assessment of Etravirine Plus Darunavir/Ritonavir-Based Regimens in Treatment-Experienced Patients
TMC278-C204 Metabolic and Safety Substudies: Investigation of Rilpivirine in Treatment-Naive Patients
7-Day Monotherapy Trial of the Next-Generation NNRTI UK-453,061
MERIT: Maraviroc vs Efavirenz in the Treatment of Antiretroviral-Naive Patients
ACTG A5211: 48-Week Study of Vicriviroc in Treatment-Experienced Patients
Phase II Trials Evaluating the Investigational CCR5 Antagonists INCB009471 and PRO 140
Comparable Antiviral Activity and Accelerated Viral Decay of Raltegravir vs Efavirenz in Treatment-Naive Patients
Apricitabine vs Lamivudine in Treatment-Experienced Patients With the M184V Mutation

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.